• Users Online: 200
  • Print this page
  • Email this page
Year : 2019  |  Volume : 6  |  Issue : 2  |  Page : 92-95

Pembrolizumab-induced uveitis in a patient with metastatic urothelial carcinoma

1 Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
2 Department of Oncology; Graduate Institute of Clinical Medicine; National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei, Taiwan

Correspondence Address:
Dr. Jhe-Cyuan Guo
Department of Oncology, National Taiwan University Hospital, No. 7, Zhongshan South Road, Taipei 100-02
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JCRP.JCRP_20_18

Rights and Permissions

Immune checkpoint blockade, especially targeting the programmed cell death protein-1/programmed death-ligand 1 axis, has changed the paradigm of anticancer therapy in several cancer types. For urothelial carcinoma (UC), pembrolizumab is an immune checkpoint inhibitor approved by the US Food and Drug Administration for locally advanced or metastatic disease. The new anticancer modalities are complicated with immune-related adverse events (irAEs) which are significantly different from conventional treatment such as chemotherapy or targeted therapy. Herein, we present an 85-year-old man with metastatic UC who developed a rare kind of irAE, uveitis, under pembrolizumab therapy, who fortunately partially recovered with local and systemic steroids.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded85    
    Comments [Add]    

Recommend this journal